ImmunoPrecise Antibodies Q3 2024 GAAP EPS $(0.08) Beats $(0.10) Estimate, Sales $4.555M Miss $6.068M Estimate
Portfolio Pulse from Benzinga Newsdesk
ImmunoPrecise Antibodies (NASDAQ:IPA) reported Q3 2024 earnings with a GAAP EPS of $(0.08), surpassing the $(0.10) estimate. However, their sales of $4.555M fell short of the $6.068M estimate, marking a 24.93% miss but an 18.71% increase from the previous year.
March 14, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ImmunoPrecise Antibodies reported a better-than-expected EPS but missed sales estimates for Q3 2024, showing mixed financial results.
While beating EPS estimates typically has a positive impact on stock prices, missing sales forecasts can have a negative effect. The mixed results present a neutral outlook for IPA's stock in the short term, as the positive EPS surprise may be offset by the disappointment in sales performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100